Status:
COMPLETED
Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cocaine-Related Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to empirically test a series of medications to: 1) determine each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective dose range for eac...
Detailed Description
16-week participation plus a 2 weekk lead-in period. Participants are assigned randomly to placebo or amantadine. Participants attend group meeting 3 times/week
Eligibility Criteria
Inclusion Criteria:
M/F, ages 18-65. cocaine dependence according to DMS-IV criteria. Self-reported use within the last 30 days. Agreeable to conditions of the study and signed informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy, history of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.
Key Trial Info
Start Date :
March 1 1996
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000301
Start Date
March 1 1996
Last Update
July 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Friends Research Institute
Los Angeles, California, United States, 90025